Man Group PLC Aerie Pharmaceuticals Inc Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $569,408 - $907,059	-43,400 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $83,904 - $133,308	-9,200 Reduced 17.49%	43,400 $586,000
Q3 2020 Nov 16, 2020	BUY	$10.46 - $14.46 $550,196 - $760,596	52,600 New	52,600 $619,000
Q3 2019 Nov 14, 2019	SELL	$18.41 - $28.0 $776,589 - $1.18 Million	-42,183 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $1.22 Million - $2.03 Million	42,183 New	42,183 $1.25 Million
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $1.57 Million - $2.86 Million	-47,677 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$56.15 - $73.9 $2.68 Million - $3.52 Million	47,677 New	47,677 $2.93 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.